TNAX BIOPHARMA
TNAX Biopharma is a developer of pharmaceuticals drugs intended to improve the quality of life of patients.The company provides novel antibody therapeutics for unmet medical needs of patients with intractable diseases, thus providing patients therapeutics around the world through drug discovery innovation.
TNAX BIOPHARMA
Industry:
Biotechnology Life Science Medical Nursing And Residential Care Therapeutics
Founded:
2018-01-01
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.tnaxbio.com
Total Employee:
101+
Status:
Active
Total Funding:
999.4 M JPY
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Google Universal Analytics Font Awesome
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Current Employees Featured
Founder
Investors List
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Series A - TNAX Biopharma
Nissay Capital
Nissay Capital investment in Series A - TNAX Biopharma
JAFCO
JAFCO investment in Series A - TNAX Biopharma
JAFCO
JAFCO investment in Series A - TNAX Biopharma
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Series A - TNAX Biopharma
Nissay Capital
Nissay Capital investment in Series A - TNAX Biopharma
Official Site Inspections
http://www.tnaxbio.com
- Host name: 153.122.205.46
- IP address: 153.122.205.46
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "TNAX Biopharma"
TNAX Biopharma Corporation
TNAX Biopharma Corporation is a biopharmaceutical company focused on the development and commercialization of novel antibody therapeutics that address unmet medical needs of patients with intractable diseases.See details»
TNAX Biopharma Corp. - Drug pipelines, Patents, Clinical trials
Nov 1, 2024 tnaxbio.com. Startups | Holding Company | 2018 | Tokyo-to, Japan | 100-250 | tnaxbio.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational Medicine. …See details»
TNAX Biopharma - Crunchbase Company Profile
TNAX Biopharma is a developer of pharmaceuticals drugs intended to improve the quality of life of patients.The company provides novel antibody …See details»
TNAX Biopharma Company Profile 2024: Valuation, Funding
TNAX Biopharma General Information Description. Developer of pharmaceutical drugs intended to improve the quality of life for patients. The company's drug provides novel antibody …See details»
TNAX BIOPHARMA CORPORATION - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for TNAX BIOPHARMA CORPORATION of TSUKUBA, IBARAKI. Get the latest business insights from …See details»
TNAX Biopharma Corporation - VentureRadar
Similar Companies: Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, …See details»
TNAX Biopharma - Overview, News & Similar companies - ZoomInfo
View TNAX Biopharma (www.tnaxbio.com) location in Tokyo, Japan , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
TNAX Biopharma - Products, Competitors, Financials, Employees ...
About TNAX Biopharma. TNAX Biopharma is a biopharmaceutical company focused on the development of antibody therapeutics. It develops antibodies for the unmet medical needs of …See details»
TNAX Biopharma Corporation
TNAX Biopharma Corporation Developing first-in-class biologics which target immunoreceptors and their ligands discovered by Professor Akira Shibuya, University of Tsukuba TNAX101A = …See details»
Management Team | TNAX Biopharma Corporation
Tak Mukohira, R.Ph.,CEO & Co-founder. Tak Mukohira has over 35 years’ experience in leading pharmaceutical and healthcare companies across business development, corporate strategy …See details»
TNAX Biopharma - Company Profile - Tracxn
Oct 31, 2024 Website: tnaxbio.com; Phone Number: +81 ***** Key Metrics. Latest Funding Round. Series A, Nov 30, 2018, Undisclosed. Investors. Mitsubishi UFJ Capital & 2 more. …See details»
TNAX Biopharma株式会社 | InfoBase
TNAX Biopharma株式会社. 会社概要 「TNAX101A」という特発性肺疾患・炎症性腸疾患の治療を目的とする抗DNAM-1抗体と、「抗CD300a mAb」という急性脳虚血・腎虚血の損傷回復 …See details»
Anti-CD300a mAb (TNAX) - Drug Targets, Indications, Patents
Nov 21, 2024 Anti-CD300a mAb(TNAX): a CD300A inhibitors Drug, Initially developed by TNAX Biopharma Corp., Now, its global highest R&D status is Preclinical, Mechanism: CD300A …See details»
出資先「三菱UFJキャピタル_TNAX Biopharma_4391」｜投資済 …
筑波大学人間総合科学研究科免疫制御医学分野の渋谷彰教授の研究成果に基づいて、免疫受容体を標的とした医薬品の開発を手がける筑波大学発のスタートアップ。See details»
TNAX Biopharma was authorized as a startup originated from …
Nov 30, 2018 TNAX Biopharma was authorized as a startup originated from University of Tsukuba.(press release, university of Tsukuba)See details»
TNAX BIOPHARMA CORP. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for TNAX BIOPHARMA CORP. of CHIYODA-KU, TOKYO. Get the latest business insights from Dun & …See details»
TNAX Biopharma Corporation - VentureRadar
Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and …See details»
TNAX Biopharma Corp. (TNAX Biopharma Corp.) - 药物管线_专利_ …
了解TNAX Biopharma Corp. (TNAX Biopharma Corp.)公司的药物管线，治疗领域，技术平台，以及它的2篇新闻和4篇文献，疾病领域:神经系统疾病，免疫系统疾病，技术平台:单克隆抗体， …See details»
Science & Pipeline - TNAX Biopharma Corporation
TNAX103 is also believed to restore kidneys from AKI. Acute Kidney Injury and Efferocytosis. Acute kidney injury (AKI) occurs in up to 7% of hospitalized patients and up to 30% of ICU …See details»
News | TNAX Biopharma Corporation
Nov 30, 2018 University of Tsukuba and TNAX Biopharma Corporation identified an antibody and findings were published in Proc Natl Acad Sci USASee details»